• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»antiviral therapy

TUNE-401 gives Tune Therapeutics an early signal in the race for finite HBV therapy

By Pallavi Madhiraju on May 30, 2026   Pharma & Biotech  

TUNE-401 gives Tune Therapeutics an early signal in the race for finite HBV therapy

Find out how Tune Therapeutics’ TUNE-401 data could reshape the chronic hepatitis B cure race and what risks remain for Phase 2.

Can Bioxytran’s ProLectin-M accelerate viral clearance in mild COVID-19?

By Soujanya Ravi on March 3, 2026   Pharma & Biotech  

Can Bioxytran’s ProLectin-M accelerate viral clearance in mild COVID-19?

Bioxytran reports early antiviral signal for ProLectin-M. Discover what this means for COVID-19 treatment strategy and regulatory risk.

AiCuris pritelivir shows superior lesion healing in HIV-associated refractory HSV

By Soujanya Ravi on February 26, 2026   Pharma & Biotech  

AiCuris pritelivir shows superior lesion healing in HIV-associated refractory HSV

AiCuris pritelivir shows superior lesion healing in HIV-associated refractory HSV. Explore what the Phase 3 data mean for regulation and practice.

Recent Posts

  • Could DermaSensor’s NHS study turn AI skin cancer tools into primary care infrastructure?
  • GlycoNex targets Prolia and Xgeva space as SPD8 meets Phase III equivalence goal
  • Could KARL STORZ’s Rubina Lens turn open surgery into the next imaging battleground?
  • Elixiron’s oral Alzheimer’s drug data raise a bigger question: can neuroinflammation become the next serious treatment target?
  • Apnimed advances oral OSA therapy case as AD109 heads toward FDA decision window
  • Optimi Health’s first UK psilocybin export signals bigger test for GMP psychedelic manufacturing
  • Why Cartesian Therapeutics’ WestGene pact could intensify the race for autoimmune cell therapy
  • Why FDA alignment could move Alterity’s ATH434 closer to a pivotal MSA test
  • Why TG Therapeutics’ BRIUMVI data could open a new treatment path in myasthenia gravis
  • Harbour BioMed’s HBM7004 China IND acceptance sharpens the race for B7-H4 cancer targets
  • Sensorion’s SENS-601 strategy signals a sharper bet on larger genetic hearing loss markets
  • Can Zetagen’s ZetaMet Phase 2a data change how metastatic breast cancer bone lesions are treated?
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes